Hepatic RIG-I Predicts Survival and Interferon-Α Therapeutic Response in Hepatocellular Carcinoma.
Jin Hou,Ye Zhou,Yuanyuan Zheng,Jia Fan,Weiping Zhou,Irene O. L. Ng,Huichuan Sun,Lunxiu Qin,Shuangjian Qiu,Joyce M. F. Lee,Chung-Mau Lo,Kwan Man,Yuan Yang,Yun Yang,Yingyun Yang,Qian Zhang,Xuhui Zhu,Nan Li,Zhengxin Wang,Guoshan Ding,Shi-Mei Zhuang,Limin Zheng,Xiaoling Luo,Yuan Xie,Anmin Liang,Zhugang Wang,Ming Zhang,Qiang Xia,Tingbo Liang,Yizhi Yu,Xuetao Cao
DOI: https://doi.org/10.1016/j.ccr.2013.11.011
IF: 50.3
2014-01-01
Cancer Cell
Abstract:In hepatocellular carcinoma (HCC), biomarkers for prediction of prognosis and response to immunotherapy such as interferon-α (IFN-α) would be very useful in the clinic. We found that expression of retinoic acid-inducible gene-I (RIG-I), an IFN-stimulated gene, was significantly downregulated in human HCC tissues. Patients with low RIG-I expression had shorter survival and poorer response to IFN-α therapy, suggesting that RIG-I is a useful prognosis and IFN-α response predictor for HCC patients. Mechanistically, RIG-I enhances IFN-α response by amplifying IFN-α effector signaling via strengthening STAT1 activation. Furthermore, we found that RIG-I deficiency promotes HCC carcinogenesis and that hepatic RIG-I expression is lower in men than in women. RIG-I may therefore be a tumor suppressor in HCC and contribute to HCC gender disparity.